Sansure Biotech Inc. Annual Report 2021: Prosperous in All Aspects
Sansure Biotech Inc. released its 2021 annual report and 2022 Q1 report. Under the severe challenge of the COVID-19 pandemic, the company independently developed various products and achieved brilliant achievements. This report summarizes Sansure’s 2021 achievements, including revenue, R&D priorities, and significant future direction.
Sansure maintains a leading position in the medical industry, with stable revenue and strong resilience. In 2021, Sansure obtained 4.515 billion RMB revenue, and the net profit was 2.243 billion RMB, contributing to the total assets of 7.090 billion RMB.
Sansure took the original technology R&D as a top priority and carried out a series of innovative products with great success. The company invested 188 million RMB in R&D in 2021, with a year-on-year increase of 126.53%. On the other hand, Sansure has applied for 91 patents and registered 132 domestic and foreign products. In addition, Sansure has successfully launched some strategic new products, including Six Respiratory Pathogens Nucleic Acid Diagnostic Kit, iPonatic-Portable Molecule Workstation, etc.
Sansure has carried out over 100 research projects in various fields, including full-scenario solutions in COVID-19, blood safety, accurate detection of the respiratory tract, early detection of cancer, children’s health, etc. In 2021, Sansure gained plenty of awards, including the “Medical Innovation Award” in the G20 Innovation League, “Top 100 Enterprises of Hunan in 2021”, etc., which show its high reputation in society.
With a comprehensive upgrade of the marketing system, Sansure has occupied the market worldwide. Sansure focused on major production lines and distributed them to various districts and countries. The company has established subsidiaries in Philippines, Indonesia, and other countries. It exported its products to more than 160 countries and regions like Italy, the United Kingdom, and the United Arab Emirates.
In the face of COVID-19, Sansure took the initiative to shoulder its social responsibilities. In 2021, the team of Sansure assisted Hunan, Fujian, Shaanxi, and other provinces in fighting against the epidemic and helped with molecular testing. In December 2021, Sansure donated more than 15 million RMB of emergency supplies to the Shaanxi Red Cross Society to support the prevention and control of the pandemic. Up to now, Sansure has donated nearly 300 million RMB to several public health incidents, disaster assistance, and livelihood projects at home and abroad.
Looking forward to 2022, Sansure has made a layout that keeps pace with the times in business, including building an in vitro diagnosis ecology system. On the other hand, the company advocates the integration of the enterprise’s image, industrial chain, and talents. In addition, Sansure will strengthen the industrial chain, focusing on fundamental technologies, core modules, and materials.
In the future, Sansure will continue to strive for excellence and increase investment in R&D. With great attention to national health, Sansure will continue to promote the popularization and full-scene application of gene technology, providing the public with beneficial services.
